Clinical Trial: Phase 1 Study of HS-10541 as Monotherapy or in Combination With Other Anti-cancer Therapies in Patients With KRAS G12C Mutation Advanced Solid Tumors.

U.S., May 30 -- ClinicalTrials.gov registry received information related to the study (NCT07615413) titled 'Phase 1 Study of HS-10541 as Monotherapy or in Combination With Other Anti-cancer Therapies in Patients With KRAS G12C Mutation Advanced Solid Tumors.' on May 14.

Brief Summary: This is a multicenter, open-label phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of HS-10541 as monotherapy or in combination with other anti-cancer therapies in participants with KRAS G12C mutation advanced solid tumors.

Study Start Date: June 30

Study Type: INTERVENTIONAL

Condition: KRAS G12C Mutation Advanced Solid Tumor

Intervention: DRUG: HS-10541

HS-10541 will be administered orally once da...